12/30/2023 0 Comments Cgm findings vsIn the CGM group, compared with the BGM group, the mean percentage of CGM-measured time in the target glucose range of 70 to 180 mg/dL was 59% vs 43% (adjusted difference, 15% P < .001), the mean percentage of time at greater than 250 mg/dL was 11% vs 27% (adjusted difference, −16% P < .001), and the means of the mean glucose values were 179 mg/dL vs 206 mg/dL (adjusted difference, −26 mg/dL P < .001). Mean HbA 1c level decreased from 9.1% at baseline to 8.0% at 8 months in the CGM group and from 9.0% to 8.4% in the BGM group (adjusted difference, −0.4% P = .02). Results Among 175 randomized participants (mean age, 57 years 88 women 92 racial/ethnic minority individuals mean baseline HbA 1c level, 9.1% ), 165 (94%) completed the trial. Key secondary outcomes were CGM-measured time in target glucose range of 70 to 180 mg/dL, time with glucose level at greater than 250 mg/dL, and mean glucose level at 8 months. Main Outcomes and Measures The primary outcome was hemoglobin A 1c (HbA 1c) level at 8 months. Interventions Random assignment 2:1 to CGM (n = 116) or traditional blood glucose meter (BGM) monitoring (n = 59). Objective To determine the effectiveness of CGM in adults with type 2 diabetes treated with basal insulin without prandial insulin in primary care practices.ĭesign, Setting, and Participants This randomized clinical trial was conducted at 15 centers in the US (enrollment from July 30, 2018, to Octofollow-up completed July 7, 2020) and included adults with type 2 diabetes receiving their diabetes care from a primary care clinician and treated with 1 or 2 daily injections of long- or intermediate-acting basal insulin without prandial insulin, with or without noninsulin glucose-lowering medications. Importance Continuous glucose monitoring (CGM) has been shown to be beneficial for adults with type 2 diabetes using intensive insulin therapy, but its use in type 2 diabetes treated with basal insulin without prandial insulin has not been well studied. Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.Listing of Types of Reported Adverse Events Body Weight, Blood Pressure, and CholesterolĮTable 15. Medications Added and Stopped During Follow-upĮTable 14. Additions and Discontinuations of Diabetes Medications and Insulin UseĮTable 13. CGM Outcomes According to Time of DayĮTable 12. Change in HbA1c According to Baseline SubgroupsĮTable 10. Change in HbA1c According to Baseline HbA1c GroupĮTable 9. Change in HbA1c: Per-Protocol Analysis and Sensitivity AnalysesĮTable 8. Frequency of Blood Glucose Meter TestingĮTable 7. Glucose Lowering Medications in Use at Time of Randomization in Addition to InsulinĮTable 6. Secondary and Exploratory Study Outcomes and Additional Statistical MethodsĮTable 4. Description of Quality of Life and Satisfaction QuestionnairesĮTable 3. Mean Glucose Over 24 Hours at 8 MonthsĮTable 2. Flow Chart of Visit Completion RatesĮFigure 3.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |